Charles River Laboratories International, Inc.
CRLNYSEHealthcare● Active
$186.38
+$5.04(+2.78%)
Market Cap$9.0B
P/E Ratio—
52W High$228.88
52W Low$140.78
Charles River Laboratories International, Inc. (CRL) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · CRL · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $4.02B | $4.05B | $4.13B | $3.98B | $3.54B |
| Cost of Revenue | $2.79B | $2.72B | $2.63B | $2.51B | $2.21B |
| Gross Profit | $1.23B | $1.33B | $1.50B | $1.46B | $1.33B |
| Gross Margin %(computed) | 30.52% | 32.88% | 36.39% | 36.79% | 37.70% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.72B | $1.10B | $0.89B | $0.81B | $0.74B |
| Operating Income | $0.51B | $0.23B | $0.62B | $0.65B | $0.59B |
| Operating Margin %(computed) | 12.65% | 5.61% | 14.95% | 16.37% | 16.66% |
| Interest Income | $0.00B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.11B | $0.13B | $0.14B | $0.06B | $0.07B |
| Income Before Tax | ($0.10B) | $0.09B | $0.58B | $0.62B | $0.48B |
| Income Tax Expense | $0.04B | $0.07B | $0.10B | $0.13B | $0.08B |
| Net Income | ($0.14B) | $0.01B | $0.47B | $0.49B | $0.39B |
| Net Margin %(computed) | -3.59% | 0.25% | 11.49% | 12.23% | 11.04% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-2.91 | $0.20 | $9.27 | $9.57 | $7.77 |
| Wtd Avg Shares | 0.05B | 0.05B | 0.05B | 0.05B | 0.05B |
| EBITDA | $0.91B | $0.58B | $1.03B | $0.99B | $0.82B |
| EBITDA Margin %(computed) | 22.69% | 14.35% | 24.99% | 24.80% | 23.17% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Charles River Laboratories International, Inc. data
About Charles River Laboratories International, Inc. (CRL) Income Statement
Charles River Laboratories International, Inc. (CRL) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, CRL reported revenue of $4.02B, gross profit of $1.23B (gross margin 30.52%), and net income of ($0.14B) — a net profit margin of -3.59%.
Frequently asked questions
CRL · 4 questionsCharles River Laboratories International, Inc. (CRL) reported revenue of $4.02B for 2025, down 0.9% year-over-year.
CRL revenueCRL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08